Failure of sequential biliary stenting for unsuccessful common bile duct stone removal

AIM: To determine the factors associated with the failure of stone removal by a biliary stenting strategy. METHODS: We retrospectively reviewed 645 patients with common bile duct (CBD) stones who underwent endoscopic retrograde cholangiography for stone removal in Siriraj GI Endoscopy center, Siriraj Hospital from June 2009 to June 2012. A total of 42 patients with unsuccessful initial removal of large CBD stones that underwent sequential biliary stenting were enrolled in the present study. The demographic data, laboratory results, stone characteristics, procedure details, and clinical outcomes were recorded and analyzed. In addition, the patients were classified into two groups based on outcome, successful or failed sequential biliary stenting, and the above factors were compared. RESULTS: Among the initial 42 patients with unsuccessful initial removal of large CBD stones, there were 37 successful biliary stenting cases and five failed cases. Complete CBD clearance was achieved in 88.0% of cases. The average number of sessions needed beforecomplete stone removal was achieved was 2.43 at an average of 25 wk after the first procedure. Complications during the follow-up period occurred in 19.1% of cases, comprising ascending cholangitis (14.3%) and pancreatitis (4.8%). The factors associated with failure of complete CBD stone clearance in the biliary stenting group were unchanged CBD stone size after the first biliary stenting attempt (10.2 wk) and a greater number of endoscopic retrograde cholangio-pancreatography sessions performed (4.2 sessions). CONCLUSION: The sequential biliary stenting is an effective management strategy for the failure of initial large CBD stone removal.

Biliary metal stents should be placed near the hilar duct in distal malignant biliary stricture patients

BACKGROUND Endoscopic biliary drainage using a self-expandable metallic stent(SEMS)has been widely performed to treat distal malignant biliary obstruction(DMBO).However,the optimal position of the stent remains unclear.AIM To determine the ideal position for SEMS placement.METHODS In total,135 DMBO patients underwent SEMS(uncovered or covered)placement over a ten-year period.A total of 127 patients with biliary obstruction between the junction of the cystic duct and Vater’s papilla were enrolled.An SEMS was placed through the upper common bile duct 2 cm from the biliary hilar duct in 83 patients(Hilar group)or near the top of the biliary obstruction in 44 patients(Lower group).Technical and functional success,adverse events,and risk factors for SEMS dysfunction were evaluated.RESULTS The stent patency period was significantly longer in the Hilar group than in the Lower group(P value<0.01).In multivariate analysis,the only statistically significant risk factor for SEMS dysfunction was being in the Lower group(hazard ratio:9.94,95%confidence interval:2.25–44.0,P<0.01).CONCLUSION A longer patency period was achieved by positioning the SEMS near the biliary hilar duct.

Randomized trial in malignant biliary obstruction:Plastic vs partially covered metal stents

AIM:To compare efficacy and complications of par-tially covered self-expandable metal stent(pcSEMS)to plastic stent(PS)in patients treated for malignant,infrahilar biliary obstruction.METHODS:Multicenter prospective randomized clinical trial with treatment allocation to a pcWallstent(SEMS)or a 10 French PS.Palliative patients aged≥18,for infrahilar malignant biliary obstruction and a Karnofsky performance scale index>60%from 6 participating North American university centers.Primary endpoint was time to stent failure,with secondary outcomes of death,adverse events,Karnofsky performance score and short-form-36 scale administered on a three-monthly basis for up to 2 years.Survival analyses were performed for stent failure and death,with Cox proportional hazards regression models to determine significant predictive characteristics.RESULTS:Eighty-five patients were accrued over 37mo,42 were randomized to the SEMS group and 83patients were available for analyses.Time to stent failure was 385.3±52.5 d in the SEMS and 153.3±19.8 d in the PS group,P=0.006.Time to death did not differ between groups(192.3±23.4 d for SEMS vs211.5±28.0 d for PS,P=0.70).The only significant predictor was treatment allocation,relating to the time to stent failure(P=0.01).Amongst other measured outcomes,only cholangitis differed,being more common in the PS group(4.9%vs 24.5%,P=0.029).The small number of patients in follow-up limits longitudinal assessments of performance and quality of life.From an initially planned 120 patients,only 85 patients were recruited.CONCLUSION:Partially covered SEMS result in a longer duration till stent failure without increased complication rates,yet without accompanying measurable benefits in survival,performance,or quality of life.

New 14-mm diameter Niti-S biliary uncovered metal stent for unresectable distal biliary malignant obstruction

AIM To investigate whether an uncovered self-expandable metal stent(UCSEMS) with a large diameter could prevent recurrent biliary obstruction(RBO).METHODS Thirty-eight patients with malignant biliary obstruction underwent treatment with an UCSEMS with a 14-mm diameter(Niti-S 14). Retrospectively, we evaluated technical and functional success rate, RBO rate, time to RBO, survival time, and adverse events in these patients.RESULTS Stent placement success and functional success were achieved in all patients. Two patients(5.3%) had RBO due to tumor ingrowth or overgrowth. The median time to RBO was 190(range, 164-215) d. The median survival time was 120(range, 18-502) d. The 6-mo non-RBO rate was 91%. Other adverse events other than RBO occurred as follows: Acute cholecystitis, post-ERCP pancreatitis, hemobilia, and fever without exacerbation of liver injury, and liver abscess in 4(10.3%), 3(7.9%), 2(5.3%), 1(2.6%), and 1(2.6%), respectively. Migration of the stents was not observed.CONCLUSION Niti-S 14 is considered to be a preferable metal stent because of a low rate of RBO with no migration.

Endoscopic multiple metal stenting for the treatment of enteral leaks near the biliary orifice: A novel effective rescue procedure

Between April 2013 and October 2015, 6 patients developed periampul ary duodenal or jejunal/biliary leaks after major abdominal surgery. In all patients, percutaneous drainage of the collection or re-operation with primary surgical repair was attempted at first but failed. A fully covered enteral metal stent was placed in all patients to seal the leak. Subsequently, we cannulated the common bile duct and, in some cases, and the main pancreatic duct inserting hydrophilic guidewires through the stent after dilating the stent mesh with a dilatation balloon or breaking the meshes with Argon Plasma Beam. Finally, we inserted a fully covered biliary metal stent to drain the bile into the lumen of the enteral stent. In cases of normal proximal upper gastrointestinal anatomy, a pancreatic plastic stent was also inserted. Oral food intake was initiated when the abdominal drain outflow stopped completely. Stent removal was scheduled four to eight weeks later after a CT scan to confirm the complete healing of the fistula and the absence of any perilesional residual fluid collection. The leak resolved in five patients. One patient died two days after the procedure due to severe, pre-existing, sepsis. The stents were removed endoscopically in four weeks in four patients. In one patient we experiencedstent migration causing small bowel obstruction. In this case, the stents were removed surgically. Four patients are still alive today. They are still under follow-up and doing well. Bilio-enteral fully covered metal stenting with or without pancreatic stenting was feasible, safe and effective in treating postoperative enteral leaks near the biliopancreatic orifice in our small series. This minimally invasive procedure can be implemented in selected patients as a rescue procedure to repair these challenging leaks.

Successful stent-in-stent dilatation of the common bile duct through a duodenal prosthesis,a novel technique for malignant obstruction:A case report and review of literature

For patients suffering from both biliary and duodenal obstruction,endoscopic retrograde cholangiopancreatography(ERCP) with stent placement is the treatment of choice.ERCP through an already existing duodenal prosthesis is an uncommon procedure and furthermore no studies have reported installing a covered metal stent onto an already existing bare metal stent in the common bile duct(CBD).We describe a rare case of a stent-in-stent dilatation of the CBD through an already existing self-expanding metal stent in the second part of duodenum for the patient presenting with jaundice in setting of biliary and duodenal obstruction from pancreatic adenocarcinoma.The biliary obstruction was relieved with a decrease in bilirubin levels post-stenting.

可降解药物洗脱消化道支架的研究进展与前景

背景:目前消化道支架的临床应用较为普遍,常规的自膨胀金属及塑料支架存在易移位、取出困难、术后再狭窄等问题,可降解药物洗脱消化道支架凭借生物可降解、术后再狭窄率低等优点成为消化道支架研究的热点。目的:总结可降解药物洗脱消化道支架的研究进展,对可降解药物洗脱消化道支架的前景作出展望。方法:检索中国知网、万方、Pub Med、Web of Science数据库中1994年1月至2024年3月发表的相关文献,中文检索词为“可降解,药物洗脱支架,食管支架,胆道支架,胰管支架,肠道支架,消化道支架”,英文检索词为“biodegradable,drug-eluting stent,esophageal stent,biliary stent,pancreatic duct stent,intestinal stent,gastrointestinal stent”,最终纳入64篇文献进行综述分析。结果与结论:(1)可降解药物洗脱消化道支架以生物可降解材料为主体,搭载并局部洗脱不同治疗目的的药物,发挥物理支撑及药物治疗双重作用。通过调整支架材料性质、改进制造工艺及辅助手段可以加快或减缓支架降解速度,满足临床需求。药物洗脱技术以药物涂层、纳米颗粒、聚合物载药膜等为载药平台,使药物精准释放,提高病变部位局部药物浓度,减少药物损耗及毒性药物的全身吸收量。(2)可降解药物洗脱消化道支架主要为一种或多种功能性药物结合可生物降解聚合物、金属或纳米纤维材料。可用的功能性药物分为抗炎抗增生类、抗肿瘤类、溶石类、酶抑制剂类。(3)维持支架机械性能稳定和精准控释药物是可降解药物洗脱消化道支架现阶段需要解决的问题,开发新型可降解消化道支架,研究新型载药及释药方式、制造工艺和辅助手段是未来研究方向。

Repair of a common bile duct defect with a decellularized ureteral graft

AIM To evaluate the feasibility of repairing a common bile duct defect with a decellularized ureteral graft in a porcine model.METHODS Eighteen pigs were randomly divided into three groups. An approximately 1 cm segment of the common bile duct was excised from all the pigs. The defect was repaired using a 2 cm long decellularized ureteral graft over a T-tube(T-tube group, n = 6) or a silicone stent(stent group, n = 6). Six pigs underwent bile duct reconstruction with a graft alone(stentless group). The surviving animals were euthanized at 3 mo. Specimens of the common bile ducts were obtained for histological analysis.RESULTS The animals in the T-tube and stent groups survived until sacrifice. The blood test results were normal in both groups. The histology results showed a biliary epithelial layer covering the neo-bile duct. In contrast, all the animals in the stentless group died due to biliary peritonitis and cholangitis within two months post-surgery. Neither biliary epithelial cells nor accessory glands were observed at the graft sites in the stentless group.CONCLUSION Repair of a common bile duct defect with a decellularized ureteral graft appears to be feasible. A T-tube or intraluminal stent was necessary to reduce postoperative complications.

Pancreatic guidewire placement for achieving selective biliary cannulation during endoscopic retrograde cholangio-pancreatography

AIM: To investigate the frequency and risk factors for acute pancreatitis after pancreatic guidewire placement (P-GW) in achieving cannulation of the bile duct during endoscopic retrograde cholangio-pancreatography (ERCP). METHODS: P-GW was performed in 113 patients in whom cannulation of the bile duct was difficult. The success rate of biliary cannulation, the frequency and risk factors of post-ERCP pancreatitis, and the frequency of spontaneous migration of the pancreatic duct stent were investigated. RESULTS: Selective biliary cannulation with P-GW was achieved in 73% of the patients. Post-ERCP pancreatitis occurred in 12% (14 patients: mild, 13; moderate, 1). Prophylactic pancreatic stenting was attempted in 59% of the patients. Of the 64 patients who successfully underwent stent placement, three developed mild pancreatitis (4.7%). Of the 49 patients without stent placement, 11 developed pancreatitis (22%: mild, 10; moderate, 1). Of the five patients in whom stent placement was unsuccessful, two developed mild pancreatitis. Univariate and multivariate analyses revealed no pancreatic stenting to be the only significant risk factor for pancreatitis. Spontaneous migration of the stent was observed within two weeks in 92% of the patients who had undergone pancreatic duct stenting.CONCLUSION: P-GW is useful for achieving selective biliary cannulation. Pancreatic duct stenting after P-GW can reduce the incidence of post-ERCP pancreatitis, which requires evaluation by means of prospective randomized controlled trials.

Role of endoscopic retrograde cholangiopancreatography inthe management of benign biliary strictures:What's new?

Benign biliary strictures comprise a heterogeneous group of diseases. The most common strictures amenable to endoscopic treatment are post-cholecystectomy, post-liver transplantation, related to primary sclerosing cholangitis and to chronic pancreatitis. Endoscopic treatment of benign biliary strictures is widely used as first line therapy, since it is effective, safe, noninvasive and repeatable. Endoscopic techniques currently used are dilation, multiple plastic stents insertion and fully covered self-expandable metal stents. The main indication for dilation alone is primary sclerosing cholangitis related strictures. In the vast majority of the remaining cases, temporary placement of multiple plastic stents with/without dilation is considered the treatment of choice. Although this approach is effective, it requires multiple endoscopic sessions due to the short duration of stent patency. Fully covered self-expandable metal stents appear as a good alternative to plastic stents, since they have an increased radial diameter, longer stent patency, easier insertion technique and similar efficacy. Recent advances in endoscopic technique and various devices have allowed successful treatment in most cases. The development of novel endoscopic techniques and devices is still ongoing.

Endoscopic diagnosis and treatment of biliary leak in patients following liver transplantation:a prospective clinical study

BACKGROUND: Orthotopic liver transplantation has been widely used in patients with end-stage liver disease within the last two decades. However, the prevalence of biliary complications after liver transplantation remains high. The most common short-term biliary complication may be biliary leak. So, we examined 13 patients with biliary leak after liver transplantation, attempting to evaluate the role of endoscopic diagnosis and treatment of biliary leak and the incidence of bile duct stricture after healing of the leak. METHODS: Six cases of T-tube leak and seven cases of anastomosis leak complicating liver transplantation were enrolled in this prospective study. Six patients were treated by endoscopic plastic stent placement, two by nasobiliary catheter drainage, two by papillosphincterotomy, and three by nasobiliary catheter drainage combined with plastic stent placement. Some patients received growth hormone treatment. RESULTS: The bile leak resolution time was 10-35 days in 10 patients with complete documentation. The median time of leak resolution was 15.3 days. Four cases of anastomosis stricture, three cases of common hepatic duct and one case of multiple bile duct stenosis were detected by follow-up nasobiliary catheter cholangiography or endoscopic retrograde cholangiopancreatography. CONCLUSIONS: Endoscopic nasobiliary catheter or plastic stent placement is a safe and effective treatment for bile duct stricture occurring after bile leak resolution in most liver transplantation patients. Nasobiliary catheter combined with plastic stent placement may be the best choice for treating bile leak, because, theoretically, it may prevent the serious condition resulting from accidental nasobiliary catheter dislocation, and it may have prophylactic effects on upcoming bile duct stricture, although this should be further confirmed.

Endoscopic ultrasound-guided biliary drainage-current status and future perspectives

Endoscopic retrograde cholangiopancreatography(ERCP)with stenting is the treatment modality of choice for patients with benign and malignant bile duct obstruction.ERCP could fail in cases of duodenal obstruction,duodenal diverticulum,ampullary neoplastic infiltration or surgically altered anatomy.In these cases percutaneous biliary drainage(PTBD)is traditionally used as a rescue procedure but is related to high morbidity and mortality and lower quality of life.Endoscopic ultrasound-guided biliary drainage(EUS-BD)is a relatively new interventional procedure that arose due to the development of curvilinear echoendoscope and the various endoscopic devices.A large amount of data is already collected that proves its efficacy,safety and ability to replace PTBD in cases of ERCP failure.It is also possible that EUS-BD could be chosen as a first-line treatment option in some clinical scenarios in the near future.Several EUS-BD techniques are developed EUS-guided transmural stenting,antegrade stenting and rendezvous technique and can be personalized depending on the individual anatomy.EUS-BD is normally performed in the same session from the same endoscopist in case of ERCP failure.The lack of training,absence of enough dedicated devices and lack of standardization still makes EUS-BD a difficult and not very popular procedure,which is related to life-threatening adverse events.Developing training models,dedicated devices and guidelines hopefully will make EUS-BD easier,safer and well accepted in the future.This paper focuses on the technical aspects of the different EUS-BD procedures,available literature data,advantages,negative aspects and the future perspectives of these modalities.

How do we manage post-OLT redundant bile duct?

AIM: To address endoscopic outcomes of post-Orthotopic liver transplantation (OLT) patients diagnosed with a "redundant bile duct" (RBD). METHODS: Medical records of patients who underwent OLT at the Liver Transplant Center, University Texas Health Science Center at San Antonio Texas were retrospectively analyzed. Patients with suspected biliary tract complications (BTC) underwent endoscopic retrograde cholangiopancreatography (ERCP). All ERCP were performed by experienced biliary endoscopist. RBD was defined as a looped, sigmoid-shaped bile duct on cholangiogram with associated cholestatic liver biomarkers. Patients with biliary T-tube placement, biliary anastomotic strictures, bile leaks, bile-duct stonessludge and suspected sphincter of oddi dysfunction were excluded. Therapy included single or multiple biliary stents with or without sphincterotomy. The incidence of RBD, the number of ERCP corrective sessions, and the type of endoscopic interventions were recorded. Successful response to endoscopic therapy was defined as resolution of RBD with normalization of associated cholestasis. Laboratory data and pertinent radiographic imaging noted included the pre-ERCP period and a follow up period of 6-12 mo after the last ERCP intervention. RESULTS: One thousand two hundred and eighty-two patient records who received OLT from 1992 through 2011 were reviewed. Two hundred and twenty-four patients underwent ERCP for suspected BTC. RBD was reported in each of the initial cholangiograms. Twentyone out of 1282 (1.6%) were identified as having RBD. There were 12 men and 9 women, average age of 59.6 years. Primary indication for ERCP was cholestatic pattern of liver associated biomarkers. Nineteen out of 21 patients underwent endoscopic therapy and 2/21 required immediate surgical intervention. In the endoscopically managed group: 65 ERCP procedures were performed with an average of 3.4 per patient and 1.1 stent per session. Fifteen out of 19 (78.9%) patients were successfully managed with biliary stenting. All stents were plastic. Selection of stent size and length were based upon endoscopist preference. Stent size ranged from 7 to 11.5 Fr (average stent size 10 Fr); Stent length ranged from 6 to 15 cm (average length 9 cm). Concurrent biliary sphincterotomy was performed in 10/19 patients. Single ERCP session was sufficient in 6/15 (40.0%) patients, whereas 4/15 (26.7%) patients needed two ERCP sessions and 5/15 (33.3%) patients required more than two (average of 5.4 ERCP procedures). Single biliary stent was sufficient in 5 patients; the remaining patients required an average of 4.9 stents. Four out of 19 (21.1%) patients failed endotherapy (lack of resolution of RBD and recurrent cholestasis in the absence of biliary stent) and required either choledocojejunostomy (2/4) or percutaneous biliary drainage (2/4). Endoscopic complications included: 2/65 (3%) post-ERCP pancreatitis and 2/10 (20%)non-complicated post-sphincterotomy bleeding. No endoscopic related mortality was found. The medical records of the 15 successful endoscopically managed patients were reviewed for a period of one year after removal of all biliary stents. Eleven patients had continued resolution of cholestatic biomarkers (73%). One patient had recurrent hepatitis C, 2 patients suffered septic shock which was not associated with ERCP and 1 patient was transferred care to an outside provider and records were not available for our review. CONCLUSION: Although surgical biliary reconstruction techniques have improved, RBD represents a postOLT complication. This entity is rare however, endoscopic management of RBD represents a reasonable initial approach.

Radiation therapy for extrahepatic bile duct cancer: Current evidences and future perspectives

Extrahepatic bile duct cancer (EBDC) is a rare malignancy that involves neoplastic changes extending from both hepatic ducts to the common bile duct. The treatment of choice is surgical resection, but the predominant pattern of initial treatment failure is locoregional recurrence. Accordingly, adjuvant radiotherapy has been administered after surgical resection based on these rationales. At this time, there is minimal evidence supporting adjuvant radiotherapy, because there have been no phase III trials evaluating its benefit. Relatively small retrospective studies have tried to compare outcomes associated with EBDC treated with or without radiotherapy. We aimed to review studies investigating adjuvant radiotherapy for resected EBDC. Because less than onethird of EBDC cases are amenable to curative resection at diagnosis, other locoregional treatment modalities need to be considered, including radiotherapy. The next aim of this review was to summarize reports of definitive radiotherapy for unresectable EBDC. Patients with advanced EBDC often experience biliary obstruction, which can lead to jaundice and progress to death. Biliary stent insertion is an important palliative procedure, but stents are prone to occlusion after subsequent ingrowth of the EBDC. Radiotherapy can be effective for maintaining the patency of inserted stents. We also reviewed the benefit of palliative radiotherapy combined with the biliary stent insertion. Lastly, we discuss the existing gaps in the evidence supporting radiotherapy in the management of EBDC.

胰管支架置入对急性胆源性胰腺炎患者预后及并发症的影响

目的分析急性胆源性胰腺炎(ABP)患者应用胰管支架置入治疗对预后及并发症的影响。方法选取2019年1月至2022年12月收治的300例ABP患者,按治疗方法不同分组,A组100例行鼻胆管引流治疗,B组100例行开腹胆总管探查联合T型管引流术治疗,C组100例行鼻胆管引流联合胰管支架置入治疗,对比3组肝功能、并发症、死亡率及恢复情况。结果B组术后总胆红素(TBIL)、天冬酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)水平低于A组(P<0.05);C组术后TBIL、AST、ALT水平低于A组和B组(P<0.05);B组恢复进食时间、体温恢复时间、住院时间较A组更短(P<0.05);C组恢复进食时间、腹痛消失时间、体温恢复时间及住院时间短于A组和B组(P<0.05);C组并发症发生率4.00%低于A组的12.00%(P<0.05);C组1.00%死亡率低于A组8.00%(P<0.05)。结论ABP患者应用胰管支架置入治疗,可有缩短患者恢复时间,有利于改善肝功能,死亡率低,且并发症少。

胆宁片在ERCP碎石术后留置胆管支架患者中的应用效果观察

目的评价胆宁片在ERCP碎石术后留置胆管支架患者中的应用效果。方法回顾性分析2022年9月至2023年8月同济大学附属东方医院247例实施ERCP碎石术后留置胆管支架患者的临床资料,按照术后是否服用胆宁片分为观察组(n=135)和对照组(n=112),其中观察组服用胆宁片,对照组不服用胆宁片。比较两组支架通畅率、肠胆返流率、结石残留率,以及总胆红素(TBIL)、结合胆红素(DBIL)、碱性磷酸酶(ALP)、γ-谷氨酰转移酶(GGT)的改善情况。结果与对照组比较,观察组胆管支架通畅率[89.63%(121/135)vs 57.14%(64/112),χ^(2)=34.36,P<0.001]较高,但肠胆反流发生率[8.89%(12/135)vs 33.21%(26/112),χ^(2)=23.77,P<0.001]和结石残留率均较低[13.33%(18/135)vs 23.21%(26/112),χ^(2)=8.133,P=0.004],差异有统计学意义(均P<0.05),而TBIL、DBIL、ALP和GGT均有降低,但仅有GGT的差异有统计学意义(P<0.05)。结论ERCP术后服用胆宁片可延长胆管支架的通畅时间,减少肠胆反流的发生及结石残留,并促进胆管酶谱的恢复。

CT联合分泌型卷曲受体蛋白4及可溶性生长刺激表达基因2蛋白对恶性胆道梗阻患者术后并发胰腺炎的诊断价值

目的探讨计算机断层扫描(CT)联合血清分泌型卷曲受体蛋白4(SFRP4)及可溶性生长刺激表达基因2蛋白(sST2)对恶性胆道梗阻(MBO)患者胆管支架置入术后并发胰腺炎的诊断价值。方法选取行胆管支架置入术的243例MBO患者为研究对象,根据术后并发胰腺炎情况分为胰腺炎组105例和无胰腺炎组138例。采用酶联免疫法检测SFRP4、sST2水平,采用受试者工作特征(ROC)曲线和四表格法分析SFRP4、sST2单独及联合CT诊断术后并发胰腺炎的临床价值。结果胰腺炎组血清SFRP4、sST2水平高于无胰腺炎组,差异有统计学意义(P<0.05);血清SFRP4、sST2水平诊断术后并发胰腺炎的曲线下面积(AUC)为0.694、0.667。CT诊断术后并发胰腺炎的敏感度为76.19%,特异度为60.87%;CT联合血清SFRP4、sST2水平诊断术后并发胰腺炎的敏感度为98.10%、准确度为76.54%;三者联合诊断的敏感度和准确度高于CT、SFRP4、sST2单独诊断,差异有统计学意义(P<0.05)。结论胆管支架置入术后并发胰腺炎的MBO患者血清SFRP4、sST2水平较高,CT联合血清SFRP4、sST2水平对术后并发胰腺炎具有较高的诊断价值。

高危老年胆总管大结石患者塑料胆管支架置入后支架堵塞的影响因素分析

目的探讨合并慢性病的高危老年胆总管大结石患者,经塑料胆管支架置入治疗后影响支架堵塞的危险因素。方法回顾性分析2016年1月至2024年3月因胆总管大结石在解放军总医院第一医学中心行ERCP下塑料胆管支架置入治疗的高危老年患者资料,所有患者均随访3个月并在3个月内行第二次ERCP治疗。根据患者是否出现支架堵塞将患者分为堵塞组和通畅组。比较两组间的一般资料、化验结果、结石大小、是否存在壶腹周围憩室、支架种类和直径等指标,采用多因素logistics回归分析评估影响塑料胆管支架堵塞的危险因素。结果共入组111例患者,其中堵塞组28例,通畅组83例,支架堵塞率为25.23%。单因素分析示术前白细胞计数、丙氨酸氨基转移酶、壶腹周围憩室、支架直径在两组之间比较,差异有统计学意义(P值均<0.05)。多因素logistics回归分析显示,WBC[OR(95%CI):1.209(1.074~1.361)]、支架直径[OR(95%CI):0.279(0.088~0.887)]、壶腹周围憩室[OR(95%CI):3.396(1.077~10.710)]是术后支架堵塞的独立危险因素(P值均<0.05)。结论术前白细胞计数升高及存在壶腹周围憩室的患者术后发生支架堵塞的风险高,直径更大的胆管支架可有效降低术后支架堵塞的风险。

经皮肝穿刺胆管引流联合经皮空肠穿刺引流治疗胆总管囊肿切除术后肝内胆管结石

目的 评估经皮肝穿刺胆管引流(PTCD)联合经皮空肠穿刺引流(PJD)治疗胆总管囊肿切除术后肝内胆管结石的临床价值。方法 回顾性分析2022年1月至2023年12月同济大学附属东方医院采取PTCD联合PJD治疗的16例胆总管囊肿切除术后肝内胆管结石患者的临床资料,总结治疗体会。结果 16例患者中,诊断为肝内胆管结石6例,肝内胆管结石合并胆肠吻合口狭窄7例,肝内胆管结石合并左肝管狭窄3例;7例因梗阻性黄疸于外院行PTCD,7例未能找到确切的胆肠吻合的空肠襻,2例引流管穿刺进十二指肠。在我院的9例患者均成功实施PTCD,其中左肝管3例,右肝管6例,未发生出血、胆漏、气胸等并发症。16例患者在PTCD引导下成功实施PJD并完成瘘道扩张术,未发生出血、肠漏等并发症。经皮空肠胆道镜(PJCS)下球囊扩张解除胆肠吻合口及左肝管狭窄,经过3~6次胆道镜操作取净肝内胆管结石。5例胆肠吻合口狭窄患者及3例左肝管狭窄经PTCD瘘道置入全覆膜金属支架(FCMS),FCMS留置6~9个月无移位,经PTCD瘘道取出FCMS后,行经皮经肝胆道镜(PTCS)或PJCS检查见吻合口通畅、吻合口黏膜移行良好。随访5~16个月未发现狭窄复发病例。结论 PJD为胆总管囊肿切除术后肝内胆管结石的胆道镜治疗提供了一条便捷路径,PTCD引导不仅能增加PJD成功率,还能降低FCMS的移位率。